A Phase 3 interventional study of Dulaglutide and Glimepiride in Type 2 Diabetes Mellitus, sponsored by Eli Lilly and Company. Completed at 30 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-09-18.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 — 3 open to participants now, 4 under way, 1 of them phase 3. dulaglutide · Diabetes Mellitus, Type 2.
Among the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, this one is the 10th largest by enrollment, is one of 8 that started in 2012, is one of 22 in phase 3, and was the 26th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →3 of the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States, Argentina, Mexico
Ages 10–17
First Affiliated Hospital of Wannan Medical College
Ages 18+
Seoul National University Bundang Hospital
Ages 20–90
By country, each count listing its studies:
dulaglutide: first FDA approval 2014 (TRULICITY), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 6 · Phase 3 23 · Phase 4 9
First in 2008; this study’s year is marked. 8 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 737 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 159 across the 54 interventional studies. Of the 47 that completed or were terminated, 38 (81%) have results posted.
This tab as a report to print or save as PDF → With an account.
45 of 54 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company: 10 open now, 21 under way, 11 of them phase 3. Of 211 finished, 155 (73%) have results posted.
Among the 238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company, this one is the 41st largest by enrollment of the 232 interventional ones that give a count, is one of 14 that started in 2012, is one of 85 in phase 3, and was the 89th registered.
Eli Lilly and Company’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
1 of the studies testing dulaglutide in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07537088First Affiliated Hospital of Wannan Medical CollegeEfficacy and Safety of Triple Therapy With Dulaglutide, SGLT2 Inhibitors, and Finerenone in Chinese Adults With Type 2 Diabetes and Chronic Kidney Disease | 2027-04 |
Add it to your calendar (.ics) → With an account.
Among the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 238 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to examine if once-weekly dulaglutide is efficient and safe compared to glimepiride in participants with type 2 diabetes mellitus who have inadequate glycemic control with oral antihyperglycemic medication (OAM) or are OAM-naïve.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
1.5 milligrams (mg) dulaglutide administered as one subcutaneous (SC) injection once-weekly plus one to three capsules of placebo each day for blinding purposes for up to 26 weeks.
Drug: Dulaglutide · Drug: Placebo as Capsules
0.75 mg dulaglutide administered as one SC injection once-weekly plus one to three capsules of placebo each day for blinding purposes for up to 26 weeks.
Drug: Dulaglutide · Drug: Placebo as Capsules
1 to 3 mg per day (mg/day) glimepiride administered orally as one to three capsules per day plus one SC injection of placebo once-weekly for blinding purposes for up to 26 weeks.
Drug: Glimepiride · Drug: Placebo as SC Injection
Administered SC
Also known as: LY2189265
Administered orally
Placebo for glimepiride is administered orally as one to three capsules daily.
Placebo for dulaglutide is administered as one SC injection.
Change From Baseline in HbA1c at 26 Weeks
HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) analysis adjusting for treatment, country, pre-study therapy stratum, visit, and treatment-by-visit as fixed effects; baseline HbA1c as covariate; and participant as a random effect.
Time frame: Baseline, 26 Weeks
Percentage of Participants Attaining HbA1c of <7% or ≤6.5% at 26 Weeks
Percentages of participants who achieved HbA1c levels of \<7% or ≤6.5% were analyzed using a logistic regression model, controlling for treatment, pre-treatment, baseline HbA1c and country.
Time frame: 26 Weeks
Change From Baseline in Fasting Blood Glucose (FBG) at 26 Weeks
FBG is a test to determine how much glucose (sugar) is in a blood sample after an overnight fast. FBG was measured by a central laboratory. LS means were calculated using MMRM analysis adjusting for treatment, country, pre-study therapy stratum, visit, and treatment-by-visit as fixed effects; baseline FBG as covariate; and participant as a random effect.
Time frame: Baseline, 26 Weeks
Change From Baseline in 7-point Self-monitored Blood Glucose (SMBG) Profiles at 26 Weeks
Change from baseline in mean daily blood glucose (BG) values were measured with a 7-point SMBG profile. Participants recorded their 7-point SMBG profiles on 2 separate, non-consecutive days during the 2-week period immediately before randomization, Week 8, Week 16, and Week 26 (or the Early Discontinuation Visit). The 7-point SMBG profile consisted of pre-prandial BG measures before the morning (fasting), midday, and evening meals; BG measures 2 hours after the start (post-prandial) of the morning, midday, and evening meals; and BG measures at bedtime. Mean at 26 weeks was assessed in all treatment groups. LS means were calculated using MMRM analysis adjusting for treatment, country, pre-study therapy stratum, visit, and treatment-by-visit as fixed effects; baseline body weight as covariate; and participant as a random effect.
Time frame: Baseline, 26 Weeks
Rate of Hypoglycemic Episodes
Hypoglycemic episodes are defined as events that are associated with reported signs and symptoms of hypoglycemia and/or documented BG concentrations of ≤70 milligrams per deciliter (mg/dL) (≤3.9 mmol/L). A severe hypoglycemic episode was defined as any hypoglycemic event for which the participant required the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. Nocturnal hypoglycemia is defined as any hypoglycemic event that occurs between bedtime and waking. Log mean rates of total hypoglycemia (per 30 days per participant) are presented and were calculated from negative binomial regression model. The model included country/region, prior medication group, treatment, visit, and treatment-by-visit interaction. The logarithm of days between visits was adjusted as an offset to account for possible unequal duration between visits and between participants.
Time frame: Baseline through 26 Weeks
Number of Participants With Self-Reported Hypoglycemic Episodes
The overall number of participants with self-reported hypoglycemic episodes is presented.
Time frame: Baseline through 26 Weeks
Change From Baseline in Homeostasis Model Assessment 2 Steady-state Beta (β) - Cell Function (HOMA2-%B) at 26 Weeks
Change from baseline in HOMA2-%B was assessed by using the homeostasis model assessment (HOMA) to quantify β-cell function. HOMA2-%B is a computer model that uses FBG, insulin, and C-peptide concentrations to estimate steady state β-cell function (%B) as a percentage of a normal reference population (normal young adults). The normal reference population was set at 100%. LS means were calculated using an analysis of covariance (ANCOVA) model with country, baseline, pre-treatment, and treatment as fixed effects.
Time frame: Baseline, up to 26 Weeks
Change From Baseline in Homeostasis Model Assessment 2 Insulin Sensitivity - Cell Function (HOMA2-%S) at 26 Weeks
Change from baseline in HOMA2-%S was assessed by using the HOMA to quantify insulin sensitivity. HOMA2-%S is a computer model that uses fasting plasma insulin and glucose concentrations to estimate steady state insulin sensitivity (%S) as a percentage of a normal reference population (normal young adults). The normal reference population was set at 100%. LS means were calculated using an ANCOVA model with country, baseline, pre-treatment, and treatment as fixed effects.
Time frame: Baseline, up to 26 Weeks
Change From Baseline in Pancreatic Enzymes at 26 Weeks
Amylase (total and pancreas-derived) and lipase concentrations were measured.
Time frame: Baseline, 26 Weeks
Change From Baseline in Serum Calcitonin at 26 Weeks
Time frame: Baseline, 26 Weeks
Change From Baseline in Sitting Blood Pressure at 26 Weeks
Sitting systolic blood pressure (SBP) and sitting diastolic blood pressure (DBP) were measured. LS means were calculated using MMRM analysis adjusting for treatment, country, pre-study therapy stratum, visit, and treatment-by-visit as fixed effects; baseline blood pressure as covariate; and participant as a random effect.
Time frame: Baseline, 26 Weeks
Change From Baseline in Sitting Pulse Rate at 26 Weeks
LS means were calculated using MMRM analysis adjusting for treatment, country, pre-study therapy stratum, visit, and treatment-by-visit as fixed effects; baseline pulse rate as covariate; and participant as a random effect.
Time frame: Baseline, 26 Weeks
Change From Baseline in Electrocardiogram (ECG) Parameters, Fridericia Corrected QT (QTcF) Interval and P-R Wave (PR) Interval at 26 Weeks
The QT interval is a measure of the time between the start of the Q wave and the end of the T wave and was calculated from electrocardiogram (ECG) data using Fridericia's formula: QTcF = QT/RR\^0.33. Corrected QT (QTc) is the QT interval corrected for heart rate and R-R wave (RR), which is the interval between two R waves. PR is the interval between the P wave and the ventricular depolarization wave (QRS) complex.
Time frame: Baseline, 26 Weeks
Change From Baseline in Heart Rate From ECG at 26 Weeks
Time frame: Baseline, 26 Weeks
Change From Baseline in Body Weight at 26 Weeks
LS means were calculated using MMRM analysis adjusting for treatment, country, pre-study therapy stratum, visit, and treatment-by-visit as fixed effects; baseline body weight as covariate; and participant as a random effect.
Time frame: Baseline, 26 Weeks
Change From Baseline in Body Mass Index (BMI) at 26 Weeks
BMI is an estimate of body fat based on body weight divided by height squared. LS means were calculated using MMRM analysis adjusting for treatment, country, pre-study therapy stratum, visit, and treatment-by-visit as fixed effects; baseline body weight as covariate; and participant as a random effect.
Time frame: Baseline, 26 Weeks
Percentage of Participants Developing Antibodies to Dulaglutide
Dulaglutide anti-drug antibodies (ADA) were assessed at baseline and 26 weeks. A participant was considered to have treatment-emergent dulaglutide ADA if the participant had at least 1 titer that was treatment-emergent relative to baseline, defined as a 4-fold or greater increase in titer from baseline measurement.
Time frame: Baseline through 26 Weeks
Number of Participants With Adjudicated Cardiovascular Events
Deaths and nonfatal cardiovascular adverse events (AEs) were adjudicated by a committee of physicians with cardiology expertise external to the Sponsor. The nonfatal cardiovascular AEs that were adjudicated included myocardial infarction; hospitalization for unstable angina; hospitalization for heart failure; coronary interventions (such as coronary artery bypass graft or percutaneous coronary intervention); and cerebrovascular events, including cerebrovascular accident (stroke) and transient ischemic attack. A summary of serious and other non-serious AEs regardless of causality, is located in the Reported Adverse Events module.
Time frame: Baseline through 26 Weeks
Number of Participants With Adjudicated Pancreatitis
The number of adjudicated (by an independent committee of expert physicians) pancreatic events is summarized at 26 weeks. A summary of serious and other non-serious AEs regardless of causality is located in the Reported Adverse Events module.
Time frame: Baseline through 26 Weeks
European Quality of Life Questionnaire-5 Dimensions (EQ-5D) Health State Score Responses at 26 Weeks
The EQ-5D questionnaire is a widely used, generic questionnaire that assesses 5 dimensions associated with quality of life (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). Each dimension has 3 possible levels of response: no problem, some problem, and extreme problem. Additional categories of response include ambiguous and missing. The number of participants per each of the 5 response categories is summarized for each of the 5 dimensions.
Time frame: Week 26
Visual Analog Scale (VAS) Score at 26 Weeks
The EQ-5D questionnaire is a widely used, generic questionnaire that assesses health-related quality of life and consists of a 100-milliliter (mm) visual analog scale (VAS) on which the participant rated their perceived health state on that day from 0-mm (worst imaginable health state) to 100-mm (best imaginable health state).
Time frame: Week 26
| Milestone | 1.5 mg Dulaglutide | 0.75 mg Dulaglutide | Glimepiride |
|---|---|---|---|
| Started | 244 | 248 | 245 |
| Received at least one dose of study drug | 244 | 248 | 243 |
| Modified intent-to-treat population | 239 | 239 | 242 |
| Completed | 222 | 224 | 230 |
| Not completed | 22 | 24 | 15 |
| Withdrew: Adverse event | 6 | 1 | 2 |
| Withdrew: Death | 0 | 1 | 0 |
| Withdrew: Lost to follow-up | 3 | 8 | 0 |
| Withdrew: Protocol violation | 1 | 1 | 0 |
| Withdrew: Withdrawal by subject | 11 | 12 | 12 |
| Withdrew: Physician decision | 1 | 1 | 1 |
HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) analysis adjusting for treatment, country, pre-study therapy stratum, visit, and treatment-by-visit as fixed effects; baseline HbA1c as covariate; and participant as a random effect.
| percentage of HbA1c | 1.5 mg Dulaglutide | 0.75 mg Dulaglutide | Glimepiride |
|---|---|---|---|
| Change From Baseline in HbA1c at 26 Weeks | -1.48 ± 0.069 | -1.22 ± 0.069 | -0.92 ± 0.069 |
Percentages of participants who achieved HbA1c levels of \<7% or ≤6.5% were analyzed using a logistic regression model, controlling for treatment, pre-treatment, baseline HbA1c and country.
| percentage of participants | 1.5 mg Dulaglutide | 0.75 mg Dulaglutide | Glimepiride |
|---|---|---|---|
| HbA1c ≤6.5% | 59.4 | 47.7 | 41.3 |
| HbA1c <7.0% | 74.1 | 63.6 | 57.4 |
FBG is a test to determine how much glucose (sugar) is in a blood sample after an overnight fast. FBG was measured by a central laboratory. LS means were calculated using MMRM analysis adjusting for treatment, country, pre-study therapy stratum, visit, and treatment-by-visit as fixed effects; baseline FBG as covariate; and participant as a random effect.
| millimoles per liter (mmol/L) | 1.5 mg Dulaglutide | 0.75 mg Dulaglutide | Glimepiride |
|---|---|---|---|
| Change From Baseline in Fasting Blood Glucose (FBG) at 26 Weeks | -2.71 ± 0.135 | -2.26 ± 0.137 | -1.89 ± 0.136 |
Change from baseline in mean daily blood glucose (BG) values were measured with a 7-point SMBG profile. Participants recorded their 7-point SMBG profiles on 2 separate, non-consecutive days during the 2-week period immediately before randomization, Week 8, Week 16, and Week 26 (or the Early Discontinuation Visit). The 7-point SMBG profile consisted of pre-prandial BG measures before the morning (fasting), midday, and evening meals; BG measures 2 hours after the start (post-prandial) of the morning, midday, and evening meals; and BG measures at bedtime. Mean at 26 weeks was assessed in all treatment groups. LS means were calculated using MMRM analysis adjusting for treatment, country, pre-study therapy stratum, visit, and treatment-by-visit as fixed effects; baseline body weight as covariate; and participant as a random effect.
| mmol/L | 1.5 mg Dulaglutide | 0.75 mg Dulaglutide | Glimepiride |
|---|---|---|---|
| Morning (fasting) | -2.47 ± 0.092 | -1.91 ± 0.092 | -1.80 ± 0.091 |
| Morning (2 hours post-prandial) meal | -4.56 ± 0.180 | -3.75 ± 0.181 | -3.20 ± 0.179 |
| Midday (pre-prandial) meal | -3.09 ± 0.151 | -2.43 ± 0.151 | -2.37 ± 0.150 |
| Midday (2 hours post-prandial) meal | -4.15 ± 0.174 | -3.40 ± 0.174 | -2.58 ± 0.173 |
| Evening (pre-prandial) meal | -2.36 ± 0.135 | -1.77 ± 0.136 | -1.69 ± 0.134 |
| Evening (2 hours post-prandial) meal | -3.63 ± 0.164 | -2.80 ± 0.165 | -2.35 ± 0.164 |
| Bedtime | -3.22 ± 0.152 | -2.69 ± 0.152 | -2.03 ± 0.150 |
Hypoglycemic episodes are defined as events that are associated with reported signs and symptoms of hypoglycemia and/or documented BG concentrations of ≤70 milligrams per deciliter (mg/dL) (≤3.9 mmol/L). A severe hypoglycemic episode was defined as any hypoglycemic event for which the participant required the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. Nocturnal hypoglycemia is defined as any hypoglycemic event that occurs between bedtime and waking. Log mean rates of total hypoglycemia (per 30 days per participant) are presented and were calculated from negative binomial regression model. The model included country/region, prior medication group, treatment, visit, and treatment-by-visit interaction. The logarithm of days between visits was adjusted as an offset to account for possible unequal duration between visits and between participants.
| episodes/participant/30 days | 1.5 mg Dulaglutide | 0.75 mg Dulaglutide | Glimepiride |
|---|---|---|---|
| All Hypoglycemic Episodes | 0.01 ± 0.053 | 0.01 ± 0.041 | 0.09 ± 0.581 |
| Severe Hypoglycemic Episodes | NA ± NA | NA ± NA | NA ± NA |
| Nocturnal Hypoglycemic Episodes | 0.00 ± 0.011 | 0.00 ± 0.010 | 0.01 ± 0.057 |
The overall number of participants with self-reported hypoglycemic episodes is presented.
| participants | 1.5 mg Dulaglutide | 0.75 mg Dulaglutide | Glimepiride |
|---|---|---|---|
| Number of Participants With Self-Reported Hypoglycemic Episodes | 14 | 9 | 38 |
Change from baseline in HOMA2-%B was assessed by using the homeostasis model assessment (HOMA) to quantify β-cell function. HOMA2-%B is a computer model that uses FBG, insulin, and C-peptide concentrations to estimate steady state β-cell function (%B) as a percentage of a normal reference population (normal young adults). The normal reference population was set at 100%. LS means were calculated using an analysis of covariance (ANCOVA) model with country, baseline, pre-treatment, and treatment as fixed effects.
| percentage of HOMA2-%B | 1.5 mg Dulaglutide | 0.75 mg Dulaglutide | Glimepiride |
|---|---|---|---|
| Insulin-based HOMA-2%B | 47.40 ± 2.624 | 37.92 ± 2.664 | 30.00 ± 2.591 |
| C-peptide HOMA-2%B | 41.02 ± 1.945 | 34.57 ± 1.974 | 24.58 ± 1.964 |
Change from baseline in HOMA2-%S was assessed by using the HOMA to quantify insulin sensitivity. HOMA2-%S is a computer model that uses fasting plasma insulin and glucose concentrations to estimate steady state insulin sensitivity (%S) as a percentage of a normal reference population (normal young adults). The normal reference population was set at 100%. LS means were calculated using an ANCOVA model with country, baseline, pre-treatment, and treatment as fixed effects.
| percentage of HOMA2-%S | 1.5 mg Dulaglutide | 0.75 mg Dulaglutide | Glimepiride |
|---|---|---|---|
| Insulin-Based HOMA2-%S | -6.85 ± 2.636 | -10.33 ± 2.662 | -7.19 ± 2.602 |
| C-Peptide-Based HOMA2-%S | -6.44 ± 2.056 | -11.84 ± 2.082 | -5.05 ± 2.074 |
Amylase (total and pancreas-derived) and lipase concentrations were measured.
| units per liter (u/L) | 1.5 mg Dulaglutide | 0.75 mg Dulaglutide | Glimepiride |
|---|---|---|---|
| Total amylase | 9.29 ± 16.237 | 7.04 ± 13.128 | 3.79 ± 12.538 |
| Pancreas-derived amylase | 6.19 ± 12.824 | 4.92 ± 8.123 | 2.64 ± 8.218 |
| Lipase | 10.62 ± 30.086 | 9.28 ± 22.651 | 2.38 ± 22.717 |
| picomoles per liter (pmol/L) | 1.5 mg Dulaglutide | 0.75 mg Dulaglutide | Glimepiride |
|---|---|---|---|
| Change From Baseline in Serum Calcitonin at 26 Weeks | -0.01 ± 0.318 | -0.02 ± 0.298 | 0.02 ± 1.193 |
Sitting systolic blood pressure (SBP) and sitting diastolic blood pressure (DBP) were measured. LS means were calculated using MMRM analysis adjusting for treatment, country, pre-study therapy stratum, visit, and treatment-by-visit as fixed effects; baseline blood pressure as covariate; and participant as a random effect.
| millimeters of mercury (mmHg) | 1.5 mg Dulaglutide | 0.75 mg Dulaglutide | Glimepiride |
|---|---|---|---|
| SBP | -2.07 ± 0.815 | -1.88 ± 0.813 | -0.66 ± 0.804 |
| DBP | -0.10 ± 0.535 | -0.11 ± 0.534 | 0.15 ± 0.526 |
LS means were calculated using MMRM analysis adjusting for treatment, country, pre-study therapy stratum, visit, and treatment-by-visit as fixed effects; baseline pulse rate as covariate; and participant as a random effect.
| beats per minute (bpm) | 1.5 mg Dulaglutide | 0.75 mg Dulaglutide | Glimepiride |
|---|---|---|---|
| Change From Baseline in Sitting Pulse Rate at 26 Weeks | 3.07 ± 0.581 | 1.24 ± 0.581 | -0.34 ± 0.572 |
The QT interval is a measure of the time between the start of the Q wave and the end of the T wave and was calculated from electrocardiogram (ECG) data using Fridericia's formula: QTcF = QT/RR\^0.33. Corrected QT (QTc) is the QT interval corrected for heart rate and R-R wave (RR), which is the interval between two R waves. PR is the interval between the P wave and the ventricular depolarization wave (QRS) complex.
| milliseconds (msec) | 1.5 mg Dulaglutide | 0.75 mg Dulaglutide | Glimepiride |
|---|---|---|---|
| QT interval | -6.18 ± 21.469 | -2.06 ± 19.549 | 1.21 ± 23.021 |
| PR interval | 3.73 ± 13.411 | 3.29 ± 11.236 | -0.23 ± 10.184 |
| bpm | 1.5 mg Dulaglutide | 0.75 mg Dulaglutide | Glimepiride |
|---|---|---|---|
| Change From Baseline in Heart Rate From ECG at 26 Weeks | 3.99 ± 8.459 | 1.90 ± 8.046 | 0.44 ± 9.275 |
LS means were calculated using MMRM analysis adjusting for treatment, country, pre-study therapy stratum, visit, and treatment-by-visit as fixed effects; baseline body weight as covariate; and participant as a random effect.
| kilogram (kg) | 1.5 mg Dulaglutide | 0.75 mg Dulaglutide | Glimepiride |
|---|---|---|---|
| Change From Baseline in Body Weight at 26 Weeks | -1.46 ± 0.192 | -0.77 ± 0.192 | 0.89 ± 0.190 |
BMI is an estimate of body fat based on body weight divided by height squared. LS means were calculated using MMRM analysis adjusting for treatment, country, pre-study therapy stratum, visit, and treatment-by-visit as fixed effects; baseline body weight as covariate; and participant as a random effect.
| kilograms per meter squared (kg/m^2) | 1.5 mg Dulaglutide | 0.75 mg Dulaglutide | Glimepiride |
|---|---|---|---|
| Change From Baseline in Body Mass Index (BMI) at 26 Weeks | -0.55 ± 0.070 | -0.29 ± 0.070 | 0.32 ± 0.069 |
Dulaglutide anti-drug antibodies (ADA) were assessed at baseline and 26 weeks. A participant was considered to have treatment-emergent dulaglutide ADA if the participant had at least 1 titer that was treatment-emergent relative to baseline, defined as a 4-fold or greater increase in titer from baseline measurement.
| percentage of participants | 1.5 mg Dulaglutide | 0.75 mg Dulaglutide | Glimepiride |
|---|---|---|---|
| Percentage of Participants Developing Antibodies to Dulaglutide | 17 | 8 | 4 |
Deaths and nonfatal cardiovascular adverse events (AEs) were adjudicated by a committee of physicians with cardiology expertise external to the Sponsor. The nonfatal cardiovascular AEs that were adjudicated included myocardial infarction; hospitalization for unstable angina; hospitalization for heart failure; coronary interventions (such as coronary artery bypass graft or percutaneous coronary intervention); and cerebrovascular events, including cerebrovascular accident (stroke) and transient ischemic attack. A summary of serious and other non-serious AEs regardless of causality, is located in the Reported Adverse Events module.
| number of participants | 1.5 mg Dulaglutide | 0.75 mg Dulaglutide | Glimepiride |
|---|---|---|---|
| Number of Participants With Adjudicated Cardiovascular Events | 0 | 1 | 0 |
The number of adjudicated (by an independent committee of expert physicians) pancreatic events is summarized at 26 weeks. A summary of serious and other non-serious AEs regardless of causality is located in the Reported Adverse Events module.
| participants | 1.5 mg Dulaglutide | 0.75 mg Dulaglutide | Glimepiride |
|---|---|---|---|
| Number of Participants With Adjudicated Pancreatitis | 7 | 5 | 1 |
The EQ-5D questionnaire is a widely used, generic questionnaire that assesses 5 dimensions associated with quality of life (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). Each dimension has 3 possible levels of response: no problem, some problem, and extreme problem. Additional categories of response include ambiguous and missing. The number of participants per each of the 5 response categories is summarized for each of the 5 dimensions.
| participants | 1.5 mg Dulaglutide | 0.75 mg Dulaglutide | Glimepiride |
|---|---|---|---|
| Mobility - no problem | 217 | 218 | 224 |
| Mobility - some problem | 4 | 3 | 6 |
| Mobility - extreme problem | 0 | 0 | 0 |
| Mobility - ambiguous | 0 | 0 | 0 |
| Mobility - missing | 1 | 3 | 1 |
| Self-care - no problem | 221 | 220 | 228 |
| Self-care - some problem | 0 | 1 | 2 |
| Self-care - extreme problem | 0 | 0 | 0 |
| Self-care - ambiguous | 0 | 0 | 0 |
| Self-care - missing | 1 | 3 | 1 |
| Usual activities - no problems | 221 | 219 | 228 |
| Usual activities - some problems | 0 | 2 | 2 |
| Usual activities - extreme problems | 0 | 0 | 0 |
| Usual activities - ambiguous | 0 | 0 | 0 |
| Usual activities - missing | 1 | 3 | 1 |
| Pain/Discomfort - no problems | 198 | 192 | 200 |
| Pain/Discomfort - some problems | 23 | 28 | 29 |
| Pain/Discomfort - extreme problems | 0 | 0 | 0 |
| Pain/Discomfort - ambiguous | 0 | 0 | 0 |
| Pain/Discomfort - missing | 1 | 3 | 1 |
| Anxiety/Depression - no problems | 208 | 214 | 213 |
| Anxiety/Depression - some problems | 13 | 7 | 17 |
| Anxiety/Depression - extreme problems | 0 | 0 | 0 |
| Anxiety/Depression - ambiguous | 0 | 0 | 0 |
| Anxiety/Depression - missing | 1 | 3 | 1 |
The EQ-5D questionnaire is a widely used, generic questionnaire that assesses health-related quality of life and consists of a 100-milliliter (mm) visual analog scale (VAS) on which the participant rated their perceived health state on that day from 0-mm (worst imaginable health state) to 100-mm (best imaginable health state).
| units on a scale | 1.5 mg Dulaglutide | 0.75 mg Dulaglutide | Glimepiride |
|---|---|---|---|
| Visual Analog Scale (VAS) Score at 26 Weeks | 85.72 ± 9.723 | 86.17 ± 10.744 | 85.96 ± 10.938 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 1.5 mg Dulaglutide | — | 6/244 (2.5%) | 165/244 (67.6%) |
| 0.75 mg Dulaglutide | — | 4/248 (1.6%) | 141/248 (56.9%) |
| Glimepiride | — | 3/243 (1.2%) | 137/243 (56.4%) |
| Event | 1.5 mg Dulaglutide | 0.75 mg Dulaglutide | Glimepiride |
|---|---|---|---|
| Spinal osteoarthritisMusculoskeletal and connective tissue disorders | 2/244 | 0/248 | 1/243 |
| CataractEye disorders | 0/244 | 0/248 | 1/243 |
| Cataract diabeticEye disorders | 0/244 | 0/248 | 1/243 |
| GlaucomaEye disorders | 0/244 | 0/248 | 1/243 |
| Retinal vein occlusionEye disorders | 0/244 | 0/248 | 1/243 |
| PneumoniaInfections and infestations | 0/244 | 0/248 | 1/243 |
| DyslipidaemiaMetabolism and nutrition disorders | 0/244 | 0/248 | 1/243 |
| HyperhomocysteinaemiaMetabolism and nutrition disorders | 0/244 | 0/248 | 1/243 |
| Diabetic neuropathyNervous system disorders | 0/244 | 0/248 | 1/243 |
| Supraventricular tachycardiaCardiac disorders | 1/244 | 0/248 | 0/243 |
| Event | 1.5 mg Dulaglutide | 0.75 mg Dulaglutide | Glimepiride |
|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 42/244 | 18/248 | 7/243 |
| HyperlipidaemiaMetabolism and nutrition disorders | 27/244 | 30/248 | 41/243 |
| NauseaGastrointestinal disorders | 25/244 | 13/248 | 1/243 |
| VomitingGastrointestinal disorders | 19/244 | 4/248 | 1/243 |
| Abdominal distensionGastrointestinal disorders | 16/244 | 6/248 | 5/243 |
| NasopharyngitisInfections and infestations | 16/244 | 13/248 | 13/243 |
| Lipase increasedInvestigations | 15/244 | 14/248 | 6/243 |
| Decreased appetiteMetabolism and nutrition disorders | 15/244 | 13/248 | 1/243 |
| Upper respiratory tract infectionInfections and infestations | 10/244 | 8/248 | 11/243 |
| DyslipidaemiaMetabolism and nutrition disorders | 9/244 | 9/248 | 10/243 |
Baseline characteristics is reported for the modified intent-to-treat population, who are all randomized participants with a baseline glycosylated hemoglobin (HbA1c) measurement, with at least 1 post-baseline HbA1c measurement, and who received at least one dose of study drug.
| Age, Continuous(years) | 1.5 mg Dulaglutide | 0.75 mg Dulaglutide | Glimepiride | Total |
|---|---|---|---|---|
| Mean | 52.69 ± 10.754 | 53.79 ± 10.093 | 51.97 ± 10.052 | 52.81 ± 10.317 |
| Sex: Female, Male(Participants) | 1.5 mg Dulaglutide | 0.75 mg Dulaglutide | Glimepiride | Total |
|---|---|---|---|---|
| Female | 105 | 112 | 112 | 329 |
| Male | 134 | 127 | 130 | 391 |
| Race (NIH/OMB)(Participants) | 1.5 mg Dulaglutide | 0.75 mg Dulaglutide | Glimepiride | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 239 | 239 | 242 | 720 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 0 | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | 1.5 mg Dulaglutide | 0.75 mg Dulaglutide | Glimepiride | Total |
|---|---|---|---|---|
| Taiwan | 29 | 28 | 29 | 86 |
| China | 184 | 186 | 186 | 556 |
| South Korea | 26 | 25 | 27 | 78 |
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
The record gives a start of Jul 2012, a primary completion of Aug 2014 and a completion of Aug 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2015, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dulaglutide